» Articles » PMID: 36970367

The Link Between Immunity and Hypertension in the Kidney and Heart

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertension is the primary cause of cardiovascular disease, which is a leading killer worldwide. Despite the prevalence of this non-communicable disease, still between 90% and 95% of cases are of unknown or multivariate cause ("essential hypertension"). Current therapeutic options focus primarily on lowering blood pressure through decreasing peripheral resistance or reducing fluid volume, but fewer than half of hypertensive patients can reach blood pressure control. Hence, identifying unknown mechanisms causing essential hypertension and designing new treatment accordingly are critically needed for improving public health. In recent years, the immune system has been increasingly implicated in contributing to a plethora of cardiovascular diseases. Many studies have demonstrated the critical role of the immune system in the pathogenesis of hypertension, particularly through pro-inflammatory mechanisms within the kidney and heart, which, eventually, drive a myriad of renal and cardiovascular diseases. However, the precise mechanisms and potential therapeutic targets remain largely unknown. Therefore, identifying which immune players are contributing to local inflammation and characterizing pro-inflammatory molecules and mechanisms involved will provide promising new therapeutic targets that could lower blood pressure and prevent progression from hypertension into renal or cardiac dysfunction.

Citing Articles

Resistant Hypertension: A Brief Review of Pathophysiology.

Haber A, Foy A J Gen Intern Med. 2024; 40(3):654-658.

PMID: 39402409 PMC: 11861848. DOI: 10.1007/s11606-024-09103-z.


Cardiac tissue engineering: an emerging approach to the treatment of heart failure.

Rayat Pisheh H, Nojabaei F, Darvishi A, Rayat Pisheh A, Sani M Front Bioeng Biotechnol. 2024; 12:1441933.

PMID: 39211011 PMC: 11357970. DOI: 10.3389/fbioe.2024.1441933.


Effects of Probiotics on Inflammatory Biomarkers and Its Associations With Cardiac Autonomic Function in Women With Arterial Hypertension: A Secondary Analysis of a Randomized Clinical Trial.

Maia L, de Souza J, da Silva L, Magnani M, de Souza E, Alves J Probiotics Antimicrob Proteins. 2024; .

PMID: 38842655 DOI: 10.1007/s12602-024-10303-6.


Chronic Kidney Disease Diets for Kidney Failure Prevention: Insights from the IL-11 Paradigm.

Elshoff D, Mehta P, Ziouzenkova O Nutrients. 2024; 16(9).

PMID: 38732588 PMC: 11085624. DOI: 10.3390/nu16091342.


Proteomic insights into the pathophysiology of hypertension-associated albuminuria: Pilot study in a South African cohort.

Govender M, Stoychev S, Brandenburg J, Ramsay M, Fabian J, Govender I Clin Proteomics. 2024; 21(1):15.

PMID: 38402394 PMC: 10893729. DOI: 10.1186/s12014-024-09458-9.


References
1.
Quintana A, Griesemer D, Schwarz E, Hoth M . Calcium-dependent activation of T-lymphocytes. Pflugers Arch. 2005; 450(1):1-12. DOI: 10.1007/s00424-004-1364-4. View

2.
Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C . CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014; 129(21):2111-24. DOI: 10.1161/CIRCULATIONAHA.113.007101. View

3.
Revelo X, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H . Cardiac Resident Macrophages Prevent Fibrosis and Stimulate Angiogenesis. Circ Res. 2021; 129(12):1086-1101. PMC: 8638822. DOI: 10.1161/CIRCRESAHA.121.319737. View

4.
Laurent S . Antihypertensive drugs. Pharmacol Res. 2017; 124:116-125. DOI: 10.1016/j.phrs.2017.07.026. View

5.
Taylor E, Sasser J, Maeda K, Ryan M . Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus. Am J Physiol Renal Physiol. 2019; 317(5):F1274-F1284. PMC: 6879936. DOI: 10.1152/ajprenal.00616.2018. View